Clopidogrel Sulfate Tablets 75mg (Plavix® / プラビックス錠75mg)

JPY ¥5,800

Japanese Antiplatelet Agent (Clopidogrel Sulfate 75mg). Oral tablet for prevention of ischemic cerebrovascular disease recurrence, PCI-indicated ischemic heart disease, and peripheral arterial disease thromboembolism. 100 tablets [10 tablets (PTP) x 10]. Mfd. by Sanofi K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥5,336
10 - 19 12% JPY ¥5,104
20 + 18% JPY ¥4,756
SKU: PLV-75-TAB Category:

Description

Product Overview / 商品概要

Plavix Tablets 75mg (プラビックス錠75mg)
Generic: Clopidogrel Sulfate / クロピドグレル硫酸塩
Therapeutic Category: Antiplatelet Agent / 抗血小板剤
Manufactured by: Sanofi K.K. / サノフィ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Clopidogrel 75mg (as Clopidogrel Sulfate JP 97.88mg) per tablet / クロピドグレル75mg(日局クロピドグレル硫酸塩として97.88mg)
Additives: Anhydrous lactose, Partially pregelatinized starch, Hydroxypropylcellulose, Macrogol, Tocopherol, Hydrogenated oil, Sucrose fatty acid ester, Hypromellose, Titanium oxide, Talc, Dimethylpolysiloxane, Silicon dioxide, Carnauba wax / 無水乳糖、部分アルファー化デンプン、ヒドロキシプロピルセルロース、マクロゴール、トコフェロール、硬化油、ショ糖脂肪酸エステル、ヒプロメロース、酸化チタン、タルク、ジメチルポリシロキサン、二酸化ケイ素、カルナウバロウ
Appearance: White to slightly yellowish-white film-coated tablet; diameter 8.7mm, thickness 4.9mm, weight approx. 269mg; imprint: Plavix75
外観: 白色~微黄白色・フィルムコーティング錠、直径8.7mm、厚さ4.9mm、重量約269mg、本体表示: プラビックス75

Indications / 効能効果

EN: Prevention of recurrence of ischemic cerebrovascular disease (excluding cardioembolic stroke); Ischemic heart disease applicable to percutaneous coronary intervention (PCI) including acute coronary syndrome (unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction), stable angina, and old myocardial infarction; Inhibition of thrombosis and embolism in peripheral arterial disease
JA: ○虚血性脳血管障害(心原性脳塞栓症を除く)後の再発抑制
○経皮的冠動脈形成術(PCI)が適用される下記の虚血性心疾患
 急性冠症候群(不安定狭心症、非ST上昇心筋梗塞、ST上昇心筋梗塞)
 安定狭心症、陳旧性心筋梗塞
○末梢動脈疾患における血栓・塞栓形成の抑制

Dosage and Administration / 用法用量

EN: Ischemic cerebrovascular disease (excluding cardioembolic stroke) – recurrence prevention: Usual adult dose is 75mg (as clopidogrel) orally once daily; may be reduced to 50mg once daily based on age, body weight, or symptoms.
Ischemic heart disease applicable to PCI: Loading dose of 300mg (as clopidogrel) orally once on the first day, followed by maintenance dose of 75mg orally once daily.
Peripheral arterial disease: 75mg (as clopidogrel) orally once daily.
JA: 〈虚血性脳血管障害(心原性脳塞栓症を除く)後の再発抑制〉通常、成人には、クロピドグレルとして75mgを1日1回経口投与するが、年齢、体重、症状によりクロピドグレルとして50mgを1日1回経口投与する。
〈経皮的冠動脈形成術(PCI)が適用される虚血性心疾患〉通常、成人には、投与開始日にクロピドグレルとして300mgを1日1回経口投与し、その後、維持量として1日1回75mgを経口投与する。
〈末梢動脈疾患における血栓・塞栓形成の抑制〉通常、成人には、クロピドグレルとして75mgを1日1回経口投与する。

Contraindications / 禁忌

EN: 2.1 Patients with active bleeding (e.g., hemophilia, intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage).
2.2 Patients with a history of hypersensitivity to any component of this product.
JA: 2.1 出血している患者(血友病、頭蓋内出血、消化管出血、尿路出血、喀血、硝子体出血等)
2.2 本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 21800AMZ10008
Sales Started: May 2006 / 2006年5月
Classification Code: 873399
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 100 tablets [10 tablets (PTP) x 10] / 100錠[10錠(PTP)×10]
Other Available Packages (by special order): 100 tablets [10 tablets (PTP) x 10], 140 tablets [14 tablets (PTP) x 10], 500 tablets [10 tablets (PTP) x 50], 700 tablets [14 tablets (PTP) x 50], 500 tablets [bottle, bulk]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Clopidogrel Sulfate Tablets 75mg (Plavix® / プラビックス錠75mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Clopidogrel Sulfate Tablets 75mg (Plavix®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.